Payment overview · 2025
General Payments
$2,506.84
123 reported records · 16 companies
Healthcare provider profile · identity verified
Lance W Barton, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, AR · NPI 1427085851
Verified facts
What the public records show
CMS Open Payments records show Lance W Barton, MD received $2,506.84 in general payments during 2025 across 123 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $625.50 | 24.9% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $387.52 | 15.5% | 26 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $311.72 | 12.4% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $250.60 | 10.0% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $202.05 | 8.1% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $177.39 | 7.1% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.91 | 4.8% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $103.43 | 4.1% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.56 | 2.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $58.32 | 2.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.42 | 2.1% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $47.71 | 1.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.42 | 1.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.84 | 1.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.03 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.42 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,506.84 | 123 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $515.43 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $345.40 | 19 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $302.83 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $247.88 | 23 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $219.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $200.88 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $177.39 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $171.16 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $139.84 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $139.84 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $121.83 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $106.98 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $103.43 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.18 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $62.21 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $58.32 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.42 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $47.71 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $43.15 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $42.45 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.97 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.31 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.31 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.84 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.45 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.67 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.67 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.67 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 145 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 145 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
145 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 787 | 219 |
| Lisinopril | Lisinopril | 607 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 577 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 111 |
| Omeprazole | Omeprazole | 529 | 137 |
| Gabapentin | Gabapentin | 515 | 117 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 456 | 79 |
| Meloxicam | Meloxicam | 382 | 95 |
| Metformin Hcl | Metformin Hcl | 371 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 359 | 93 |
| Tramadol Hcl | Tramadol Hcl | 307 | 74 |
| Trazodone Hcl | Trazodone Hcl | 291 | 78 |
| Furosemide | Furosemide | 290 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 71 |
| Potassium Chloride | Potassium Chloride | 268 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 70 |
| Losartan Potassium | Losartan Potassium | 254 | 66 |
| Sertraline Hcl | Sertraline Hcl | 224 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 208 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 203 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 50 |
| Simvastatin | Simvastatin | 193 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 182 | 41 |
| Celecoxib | Celecoxib | 178 | 43 |
| Clonazepam | Clonazepam | 174 | 38 |
| Lorazepam | Lorazepam | 157 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 40 |
| Alprazolam | Alprazolam | 153 | 33 |
| Ozempic | Semaglutide | 153 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 149 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 149 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 30 |
| Eliquis | Apixaban | 145 | 29 |
| Mounjaro | Tirzepatide | 145 | 28 |
| Pregabalin | Pregabalin | 139 | 31 |
| Metformin Hcl Er | Metformin Hcl | 136 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 136 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 27 |
| Allopurinol | Allopurinol | 122 | 29 |
| Montelukast Sodium | Montelukast Sodium | 110 | 26 |
| Finasteride | Finasteride | 105 | 26 |
| Estradiol | Estradiol | 102 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 102 | 20 |
| Buspirone Hcl | Buspirone Hcl | 98 | 19 |
| Carvedilol | Carvedilol | 97 | 29 |
| Ezetimibe | Ezetimibe | 93 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 29 |
| Clonidine Hcl | Clonidine Hcl | 85 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 84 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 84 | 22 |
| Bupropion Xl | Bupropion Hcl | 80 | 18 |
| Prednisone | Prednisone | 74 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 21 |
| Valsartan | Valsartan | 73 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 18 |
| Cefuroxime | Cefuroxime Axetil | 66 | 57 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 19 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Baclofen | Baclofen | 63 | suppressed |
| Ondansetron Odt | Ondansetron | 62 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 11 |
| Temazepam | Temazepam | 60 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 29 |
| Nifedipine Er | Nifedipine | 55 | 11 |
| Atenolol | Atenolol | 54 | 17 |
| Synthroid | Levothyroxine Sodium | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Diazepam | Diazepam | 52 | 11 |
| Jardiance | Empagliflozin | 49 | 11 |
| Nitroglycerin | Nitroglycerin | 49 | 41 |
| Glipizide Er | Glipizide | 48 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 48 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Farxiga | Dapagliflozin Propanediol | 45 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 11 |
| Fenofibrate | Fenofibrate | 43 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 11 |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 11 |
| Glipizide | Glipizide | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Linzess | Linaclotide | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 16 |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Nystatin | Nystatin | 23 | 12 |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Forteo | Teriparatide | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,506.84 · 123 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error